Dicerna Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$395.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Dicerna Pharmaceuticals's estimated annual revenue is currently $6.2M per year.(i)
  • Dicerna Pharmaceuticals received $100.0M in venture funding in October 2018.
  • Dicerna Pharmaceuticals's estimated revenue per employee is $20,000
  • Dicerna Pharmaceuticals's total funding is $395.5M.

Employee Data

  • Dicerna Pharmaceuticals has 309 Employees.(i)
  • Dicerna Pharmaceuticals grew their employee count by -14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body's natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic rare disease. We expect to launch two additional GalXCTM programs in 2016, including one in cardiovascular disease targeting PCSK9 and another in an undisclosed genetic rare disease. We also have the capacity to launch up to three additional programs annually, with the intent to advance five programs into the clinic by the end of 2019. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$395.5M

Total Funding

309

Number of Employees

$6.2M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Dicerna Pharmaceuticals News

2022-04-20 - Primary Hyperoxaluria Drug Market Size, Outlook And ...

Allena Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc, OxThera AB.

2022-04-20 - Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer

Prior to joining Jnana, he served as Chief Financial Officer of Dicerna Pharmaceuticals, where he oversaw the IT and Finance organizations...

2022-04-20 - Liver Diseases Therapeutics Market Size, Scope And Outlook ...

... Scope And Outlook | Astellas Pharma Inc., Bristol-Myers Squibb, ... Alnylam Pharmaceuticals Protagonist Therapeutics and Dicerna Pharmaceuticals, Inc.

2019-09-08 - Dicerna Pharmaceuticals' (NASDAQ:DRNA) Buy Rating ...

Chardan Capital reaffirmed their buy rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research note issued to investors on ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$39.7M3110%N/A
#2
$67.5M3113%$174M
#3
$40.4M31276%$2B
#4
$67.6M313-13%$16.9M
#5
$108.3M3214%N/A

Dicerna Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2008-07-16$8.4MAOxford Bioscience Partners, Skyline VenturesArticle
2010-08-12$25.0MBDomain AssociatesArticle
2010-10-22$4.0MBSR OneArticle
2013-08-02$60.0MCRA CapitalArticle
2015-05-20$UndisclosedUndisclosedJefferies LLCArticle
2017-03-31$70.0MUndisclosedBain Capital Life SciencesArticle
2017-12-15$UndisclosedUndisclosedStifelArticle
2018-09-10$115.0MUndisclosedCitigroupArticle
2018-10-31$100.0MUndisclosedEli LillyArticle